Literature DB >> 14667971

Paracrine regulation of endometrial function: interaction between progesterone and corticotropin-releasing factor (CRF) and activin A.

Pasquale Florio1, Marco Rossi, Matthildur Sigurdardottir, Pasquapina Ciarmela, Stefano Luisi, Paola Viganò, Daniela Grasso, Giovina Fiore, Luigi Cobellis, Anna Maria Di Blasio, Felice Petraglia.   

Abstract

Under the influence of ovarian steroid hormones, endometrial cells aer able to produce a wide variety of growth factors and peptide hormones that area believed to promote: (1) physiological growth and differentiation during the endometrial cycle; (2) decidualization, an essential preparative event for establishment of pregnancy; and (3) pathological growth and differentiation in endometriosis and cancer. Among the local factors produced by the human endometrium, corticotropin-releasing factor (CRF) and activin A have been evaluated in terms of localization and effects. CRF is a neuropeptide expressed by the epithelial and stromal cells of the human endometrium in increasing amounts from the endometrial proliferative to the secretory phase. CRF expression also increases in the pregnant endometrium, from early in the pregnancy until term. CRF-type 1 receptor mRNA is only expressed by stromal cells. Progesterone induces CRF gene expression and release from decidualized cells and CRF decidualizes cultured stromal endometrial cells. Urocortin, a CRF-related peptide, has been identified in endometrial epithelial and stromal cells, and its function is still under investigation. Activin A is a growth factor expressed in increasing amounts throughout endometrial phases by both epithelial and stromal cells. This growth factor is secreted into the uterine cavity with higher levels in the secretory phase. Maternal decidua expresses activin A mRNA in increasing amounts from early pregnancy until term. Human endometrium also expresses activin-A receptors and follistatin, its binding protein. Activin A decidualizes cultured human endometrial stromal cells (an effect reversed by follistatin) and modulates embryonic trophoblast differentiation and adhesion. Activin A is expressed in endometriosis and endometrial adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14667971     DOI: 10.1016/s0039-128x(03)00137-5

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  6 in total

Review 1.  Human Decidual Stromal Cells as a Component of the Implantation Niche and a Modulator of Maternal Immunity.

Authors:  Kameliya Vinketova; Milena Mourdjeva; Tsvetelina Oreshkova
Journal:  J Pregnancy       Date:  2016-04-28

2.  Chronic endometritis modifies decidualization in human endometrial stromal cells.

Authors:  Di Wu; Fuminori Kimura; Luyi Zheng; Mitsuaki Ishida; Yoko Niwa; Kimiko Hirata; Akie Takebayashi; Akiko Takashima; Kentaro Takahashi; Ryoji Kushima; Guangmei Zhang; Takashi Murakami
Journal:  Reprod Biol Endocrinol       Date:  2017-03-04       Impact factor: 5.211

3.  Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis.

Authors:  Annelyn Torres-Reverón; Leslie L Rivera-Lopez; Idhaliz Flores; Caroline B Appleyard
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

4.  Diagnostic accuracy of serum activin A in detection of ectopic pregnancy.

Authors:  Mohammad Ali Roghaei; Fahimeh Sabet; Keivan Mohamadi
Journal:  J Res Med Sci       Date:  2012-04       Impact factor: 1.852

Review 5.  The Link Between Stress and Endometriosis: from Animal Models to the Clinical Scenario.

Authors:  Caroline B Appleyard; Idhaliz Flores; Annelyn Torres-Reverón
Journal:  Reprod Sci       Date:  2020-06-15       Impact factor: 2.924

6.  Urocortin protects chondrocytes from NO-induced apoptosis: a future therapy for osteoarthritis?

Authors:  N Y Intekhab-Alam; O B White; S J Getting; A Petsa; R A Knight; H S Chowdrey; P A Townsend; K M Lawrence; I C Locke
Journal:  Cell Death Dis       Date:  2013-07-11       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.